Pioneering a path forward for patients and families.
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases. The company develops precision medicines addressing the root cause of diseases driven by the melanocortin-4 receptor (MC4R) pathway, including its lead asset IMCIVREE (setmelanotide) approved for rare genetic obesity disorders such as Bardet-Biedl syndrome and POMC deficiency. Rhythm trades on Nasdaq under the ticker RYTM.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2025
Apr 2024
Oct 2017
Nov 2012
Sep 2010
Create a free account to see which investors have funded this company.
Create Free Account
BridgeBio Pharma is a clinical-stage biopharmaceutical company developing therapies for genetic d...
R&D company with 6 SBIR/STTR awards from Department of Health and Human Services.
Health insurance company using technology to make health care simple, affordable, and accessible.
Provides comprehensive molecular profiling and AI-driven precision oncology services for physicia...
Outpatient mental health provider offering in-person and virtual therapy, psychiatry, and psychol...
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
